Professor Muresanus research contributions include: Principal investigator for the CARS trial (Cerebrolysin and Recovery After Stroke), the largest randomized controlled trial examining functional outcomes Lead investigator for CAPTAIN trials evaluating Cerebrolysin in traumatic brain injury populations Extensive research on neurotrophic factor signaling and neuroprotective mechanisms Development of multimodal therapeutic strategies combining Cerebrolysin with rehabilitation Investigations of dose-response relationships and optimal treatment protocols across neurological conditions His work has been instrumental in advancing understanding of peptidergic neuroprotection, though clinical translation challenges remain a focus of ongoing investigation
The early phase focuses on allowing your body to adjust while minimizing potential side effects as your system adapts to this gradual metabolic change
Results within 2448 hours
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, Sejersten Ripa M, Truelsen TC, Husain M
Plasma protein expression in FM has been correlated with pain severity, with an upregulation of proteins involved in immune and inflammatory processes, including upregulation of ceruloplasmin, a key acute-phase reactant (Ghafouri et al., 2023)
